Seres Therapeutics, Inc.
MCRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001609809
In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.23K in total
- 4
- 13F holdersQ2 2026, +2 vs. previous quarter
- 35
- 13F valueReported value at the end of Q2 2026
- $17.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding MCRB, Q2 2026
No superinvestor reported holding MCRB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Seres Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 (view filing)5:33 PM ET | Aug 17 | 1 day | Brady KellySee Remarks | SSale | −64 | $4.55 | −$291.2 | −0.7%8.68K after | 10b5-1 |
| Aug 18, 2026 (view filing)5:27 PM ET | Aug 17 | 1 day | Shaff Eric D.Director | SSale | −263 | $4.55 | −$1.20K | −2.1%12.5K after | 10b5-1 |
| Aug 18, 2026 (view filing)5:25 PM ET | Aug 17 | 1 day | Henn Matthew R.See Remarks | SSale | −81 | $4.55 | −$368.55 | −1.0%8.00K after | 10b5-1 |
| Aug 18, 2026 (view filing)5:22 PM ET | Aug 17 | 1 day | DesRosier ThomasSee Remarks | SSale | −82 | $4.55 | −$373.1 | −1.0%8.12K after | 10b5-1 |
| May 19, 2026 (view filing) | May 18 | 1 day | Shaff Eric D.Director | SSale | −259 | $7.53 | −$1.95K | −2.1%12.0K after | 10b5-1 |
| May 19, 2026 (view filing) | May 18 | 1 day | Brady KellySee Remarks | SSale | −59 | $7.53 | −$444.27 | −0.7%8.56K after | |
| May 19, 2026 (view filing) | May 18 | 1 day | DesRosier ThomasSee Remarks | SSale | −79 | $7.53 | −$594.87 | −1.0%7.95K after | 10b5-1 |
| May 19, 2026 (view filing) | May 18 | 1 day | Henn Matthew R.See Remarks | SSale | −77 | $7.53 | −$579.81 | −1.0%7.84K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 15 | 3 days | Young Teresa L.See Remarks | SSale | −75 | $8.47 | −$635.25 | −0.9%8.56K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 15 | 3 days | Shaff Eric D.Director | SSale | −259 | $8.47 | −$2.19K | −2.2%11.6K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Seres Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 1,155,850 | $9.12M | 0.59% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 287,776 | $2.27M | 0.00% | −6,367−2.2% | Reduced |
| Marshall Wace, LLP | 172,245 | $1.36M | 0.00% | +32,706+23.4% | Added |
| Vontobel Holding Ltd. | 122,975 | $970.3K | 0.00% | −15,493−11.2% | Reduced |
| BlackRock, Inc. | 111,000 | $875.8K | 0.00% | +8,974+8.8% | Added |
| Geode Capital Management, LLC | 79,974 | $631.3K | 0.00% | +5,139+6.9% | Added |
| Susquehanna International Group, LLP | 58,328 | $460.2K | 0.00% | −47,011−44.6% | Reduced |
| Vanguard Fiduciary Trust Co | 48,685 | $384.1K | 0.00% | +9,042+22.8% | Added |
| State Street Corp | 33,901 | $267.5K | 0.00% | 00.0% | Unchanged |
| Lion Point Capital, LP | 31,570 | $249.1K | 1.19% | 00.0% | Unchanged |